Posted by Michael Wonder on 10 Aug 2018
US FDA approves Arakoda (tafenoquine) tablets for oral use; first preventative antimalarial approved in almost two decades
9 August 2018 - 60 Degrees Pharmaceuticals announced today the U.S. FDA approval of Arakoda (tafenoquine) tablets for the prevention of malaria in patients aged 18 years and older.
For the first time in more than eighteen years, the U.S. FDA approved a new drug for the prevention of malaria.
The marketing approval of Arakoda is the culmination of years of scientific discovery and research by experts in the field of Malariology and Infectious Disease. Tafenoquine was originally discovered by scientists at the Walter Reed Army Institute of Research (WRAIR). The approval was based on a concerted effort by the U.S. Army and 60P, involving over 21 clinical trials and over 3,100 trial subjects, to develop tafenoquine as a weekly prophylactic drug for the prevention of malaria.
